

## **Personalis to Present at Upcoming Investor Conferences**

November 19, 2019

MENLO PARK, Calif.--(BUSINESS WIRE)--Nov. 19, 2019--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that Aaron Tachibana, Chief Financial Officer and Clinton Musil, Chief Business Officer, are scheduled to present at the following upcoming investor conferences

- Piper Jaffray 31<sup>st</sup> Annual Healthcare Conference on Wednesday, December 4, 2019 at 11:30 a.m. Eastern Time at the Lotte New York Palace Hotel in New York.
- Evercore ISI 2nd Annual HealthCONx Conference on Thursday, December 5, 2019 at 11:00 a.m. Eastern Time at the Four Seasons Hotel in Boston.

## About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The company's NeXTTM Platform's designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA88-certified and CAP-accredited. For more information, please visit <a href="https://www.personalis.com">www.personalis.com</a> and follow Personalis on Twitter (<a href="https://www.personalis.lnc">@Personalis.lnc</a>).

View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005053/en/

Source: Personalis, Inc.

**Investor Relations Contact for Personalis:** 

Caroline Corner investors@personalis.com 415-202-5678

**Media Contact for Personalis:** 

Jennifer Havlek pr@personalis.com www.personalis.com 650-752-1300